Literature DB >> 17109186

HBcAg-specific CD4+CD25+ regulatory T cells modulate immune tolerance and acute exacerbation on the natural history of chronic hepatitis B virus infection.

I-Che Feng1, Lok-Beng Koay, Ming-Jen Sheu, Hsing-Tao Kuo, Chi-Shu Sun, Chuan Lee, Wong-Lung Chuang, Shuen-Kuei Liao, Shih-Ling Wang, Ling-Yu Tang, Chia-Ju Cheng, Sun-Lung Tsai.   

Abstract

Acute exacerbations (AEs) of chronic hepatitis B (CH-B) are accompanied by increased T cell responses to hepatitis B core and e antigens (HBcAg/HBeAg). Why patients are immunotolerant (IT) to the virus and why AEs occur spontaneously on the immunoactive phase remain unclear. The role of HBcAg-specific CD4(+)CD25(+) regulatory T (T(reg)) cells in AE and IT phases was investigated in this study. The SYFPEITHI scoring system was employed to predict MHC class II-restricted epitope peptides on HBcAg overlapping with HBeAg that were used for T(reg)-cell cloning and for the construction of MHC class II tetramers to measure T(reg) cell frequencies (T(reg) f). The results showed that HBcAg-specific T(reg) f declined during AE accompanied by increased HBcAg peptide-specific cytotoxic T lymphocyte frequencies. Predominant Foxp3-expressing T(reg) cell clones were generated from patients on the immune tolerance phase, while the majority of Th1 clones were obtained from patients on the immunoactive phase. T(reg) cells from liver and peripheral blood of CH-B patients express CD152 and PD1 antigens that exhibit suppression on PBMCs proliferation to HBcAg. These data suggest that HBcAg peptide-specific T(reg) cells modulate the IT phase, and that their decline may account for the spontaneous AEs on the natural history of chronic hepatitis B virus infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17109186     DOI: 10.1007/s11373-006-9129-z

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  13 in total

1.  Screening and bioinformatic analysis of microRNA-associated immune clearance in patients with chronic hepatitis B.

Authors:  Tong-Jing Xing; Bian Wang; Jing Zhang
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Treatment with telbivudine positively regulates antiviral immune profiles in Chinese patients with chronic hepatitis B.

Authors:  Liang Ma; Yan-Jun Cai; Lei Yu; Jun-Yan Feng; Juan Wang; Cong Li; Jun-Qi Niu; Yan-Fang Jiang
Journal:  Antimicrob Agents Chemother       Date:  2012-12-28       Impact factor: 5.191

3.  Hepatitis B e-antigen persistency is associated with the properties of HBV-specific CD8 T cells in CHB patients.

Authors:  Guoping Peng; Benyan Luo; Jie Li; Dongjiu Zhao; Wei Wu; Feng Chen; Zhi Chen
Journal:  J Clin Immunol       Date:  2010-12-01       Impact factor: 8.317

Review 4.  Immunopathogenesis of chronic hepatitis B.

Authors:  Irina P Balmasova; Nikolay D Yushchuk; Ospan A Mynbaev; Nageswara R Alla; Elena S Malova; Zhongjie Shi; Chang-Lu Gao
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

5.  The prevalence and risk factors of hepatitis B flares in chronic hepatitis B patients receiving glucocorticoid pulse therapy.

Authors:  Ying-Cheng Lin; Shou-Wu Lee; Hong-Zen Yeh; Chi-Sen Chang; Sheng-Shun Yang
Journal:  Int J Clin Pharm       Date:  2018-01-10

6.  T follicular helper cells improve the response of patients with chronic hepatitis B to interferon by promoting HBsAb production.

Authors:  Yong Liu; Xintong Hu; Xiaoli Hu; Lei Yu; Huifan Ji; Wanyu Li; Yanjun Cai; Genhong Cheng; Yanfang Jiang
Journal:  J Gastroenterol       Date:  2022-01-06       Impact factor: 7.527

7.  Circulating CD4+ CD25+ regulatory T cells correlate with chronic hepatitis B infection.

Authors:  Guoping Peng; Shuping Li; Wei Wu; Zhen Sun; Yiqiong Chen; Zhi Chen
Journal:  Immunology       Date:  2007-08-31       Impact factor: 7.397

Review 8.  Regulatory T cells in viral hepatitis.

Authors:  Eva Billerbeck; Tobias Bottler; Robert Thimme
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

9.  Induction of regulatory T cells by high-dose gp96 suppresses murine liver immune hyperactivation.

Authors:  Xinghui Li; Zhen Liu; Xiaoli Yan; Xiaojun Zhang; Yang Li; Bao Zhao; Shengdian Wang; Xuyu Zhou; George F Gao; Songdong Meng
Journal:  PLoS One       Date:  2013-07-18       Impact factor: 3.240

10.  MiRNA-548ah, a potential molecule associated with transition from immune tolerance to immune activation of chronic hepatitis B.

Authors:  Tong-Jing Xing; Hong-Tao Xu; Wen-Qing Yu; Bian Wang; Jing Zhang
Journal:  Int J Mol Sci       Date:  2014-08-19       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.